# A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

> **NCT06208124** · PHASE1,PHASE2 · COMPLETED · sponsor: **Immuneering Corporation** · enrollment: 30 (actual)

## Conditions studied

- Advanced Solid Tumor (Phase 1)
- Pancreas Adenocarcinoma
- Non-small Cell Lung Cancer
- Malignant Melanoma (Cutaneous)

## Interventions

- **DRUG:** IMM-6-415

## Key facts

- **NCT ID:** NCT06208124
- **Lead sponsor:** Immuneering Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-27
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208124, "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06208124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*